Gd-metallofullerenol nanomaterial as non-toxic breast cancer stem cell-specific inhibitor

Ying Liu, Chunying Chen, Pengxu Qian, Xuefei Lu, Baoyun Sun, Xiao Zhang, Liming Wang, Xingfa Gao, Han Li, Zhiyun Chen, Jinglong Tang, Weijie Zhang, Jinquan Dong, Ru Bai, Peter E. Lobie, Qingfa Wu, Suling Liu, Huafeng Zhang, Feng Zhao, Max S. Wicha, Tao Zhu () and Yuliang Zhao ()
Additional contact information
Ying Liu: CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China and Institute of High Energy Physics, Chinese Academy of Sciences (CAS)
Chunying Chen: CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China and Institute of High Energy Physics, Chinese Academy of Sciences (CAS)
Pengxu Qian: Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China
Xuefei Lu: Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China
Baoyun Sun: CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China and Institute of High Energy Physics, Chinese Academy of Sciences (CAS)
Xiao Zhang: Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China
Liming Wang: CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China and Institute of High Energy Physics, Chinese Academy of Sciences (CAS)
Xingfa Gao: CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China and Institute of High Energy Physics, Chinese Academy of Sciences (CAS)
Han Li: CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China and Institute of High Energy Physics, Chinese Academy of Sciences (CAS)
Zhiyun Chen: CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China and Institute of High Energy Physics, Chinese Academy of Sciences (CAS)
Jinglong Tang: CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China and Institute of High Energy Physics, Chinese Academy of Sciences (CAS)
Weijie Zhang: Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China
Jinquan Dong: CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China and Institute of High Energy Physics, Chinese Academy of Sciences (CAS)
Ru Bai: CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China and Institute of High Energy Physics, Chinese Academy of Sciences (CAS)
Peter E. Lobie: Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China
Qingfa Wu: Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China
Suling Liu: Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China
Huafeng Zhang: Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China
Feng Zhao: CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China and Institute of High Energy Physics, Chinese Academy of Sciences (CAS)
Max S. Wicha: Comprehensive Cancer Center, University of Michigan
Tao Zhu: Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China
Yuliang Zhao: CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China and Institute of High Energy Physics, Chinese Academy of Sciences (CAS)

Nature Communications, 2015, vol. 6, issue 1, 1-18

Abstract: Abstract The contemporary use of nanomedicines for cancer treatment has been largely limited to serving as carriers for existing therapeutic agents. Here, we provide definitive evidence that, the metallofullerenol nanomaterial Gd@C82(OH)22, while essentially not toxic to normal mammary epithelial cells, possesses intrinsic inhibitory activity against triple-negative breast cancer cells. Gd@C82(OH)22 blocks epithelial-to-mesenchymal transition with resultant efficient elimination of breast cancer stem cells (CSCs) resulting in abrogation of tumour initiation and metastasis. In normoxic conditions, Gd@C82(OH)22 mediates these effects by blocking TGF-β signalling. Moreover, under hypoxic conditions found in the tumour microenvironment, cellular uptake of Gd@C82(OH)22 is facilitated where it functions as a bi-potent inhibitor of HIF-1α and TGF-β activities, enhancing CSC elimination. These studies indicate that nanomaterials can be engineered to directly target CSCs. Thus, Gd-metallofullerenol is identified as a kind of non-toxic CSC specific inhibitors with significant therapeutic potential.

Date: 2015
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/ncomms6988 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms6988

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms6988

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().